Key Points
- Director Dino Rossi sold 25,000 Krystal Biotech shares at an average price of $329.12, generating $8.23 million. The sale reduced his direct ownership by 33.33% to 50,000 shares.
- Krystal Biotech reported quarterly EPS of $1.79, beating the $1.70 analyst consensus, while revenue of $119.22 million fell slightly short of expectations.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $365.40 price target; institutional investors own 86.29% of the company.
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) Director Dino Rossi sold 25,000 shares of the company's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Krystal Biotech Stock Performance
Shares of NASDAQ:KRYS opened at $332.27 on Friday. The business's fifty day moving average price is $344.39 and its two-hundred day moving average price is $299.25. The stock has a market cap of $9.83 billion, a PE ratio of 41.64 and a beta of 0.53. Krystal Biotech, Inc. has a one year low of $136.73 and a one year high of $382.54.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts' consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The company had revenue of $119.22 million during the quarter, compared to analysts' expectations of $120.93 million. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on KRYS shares. Royal Bank Of Canada began coverage on shares of Krystal Biotech in a research note on Friday. They issued an "outperform" rating and a $400.00 target price for the company. TD Cowen raised their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a "buy" rating in a research note on Thursday, June 18th. Jefferies Financial Group reiterated a "buy" rating and set a $474.00 price target on shares of Krystal Biotech in a report on Monday, July 13th. Bank of America lifted their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a "buy" rating in a report on Tuesday, July 14th. Finally, Wall Street Zen lowered shares of Krystal Biotech from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $365.40.
View Our Latest Stock Analysis on KRYS
Institutional Investors Weigh In On Krystal Biotech
Hedge funds and other institutional investors have recently made changes to their positions in the business. UMB Bank n.a. grew its position in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock valued at $36,000 after purchasing an additional 37 shares during the period. Optimize Financial Inc lifted its position in Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company's stock worth $704,000 after buying an additional 40 shares during the period. Regal Investment Advisors LLC boosted its stake in Krystal Biotech by 1.0% in the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company's stock worth $1,075,000 after buying an additional 44 shares during the last quarter. Torray Investment Partners LLC boosted its stake in Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company's stock worth $3,108,000 after buying an additional 47 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in Krystal Biotech by 0.9% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company's stock valued at $1,537,000 after buying an additional 53 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
